Lilly bets $7.8bn on orexin science with Centessa acquisition as neuroscience race intensifies

Eli Lilly and Company (NYSE: LLY) has agreed to acquire Centessa Pharmaceuticals plc (Nasdaq: CNTA), a London-based clinical-stage company, in a transaction valued at up to $7.8 billion, including $6.3 billion in upfront cash and up to $1.5 billion in contingent milestone payments tied to U.S. regulatory approvals. The deal, announced on March 31, 2026, gives Lilly full ownership of Centessa’s pipeline of orexin receptor 2 (OX2R) agonists, a class of compounds designed to restore wakefulness by directly targeting the neurobiological system that governs the sleep-wake cycle. Centessa’s lead candidate, cleminorexton (formerly ORX750), has completed Phase 2a studies across narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia, positioning it as a potential challenger to Takeda Pharmaceutical’s orexin drug oveporexton, which is currently the frontrunner in the field. For Eli Lilly, whose stock has traded between $623.78 and $1,133.95 over the past 52 weeks and closed at approximately $919.77 on March 31 before surging roughly 4% on April 1 following a separate FDA approval, the Centessa deal is its largest acquisition since 2019 and represents a strategic opening into a therapeutic area where it has previously had no credible presence.

Why is Eli Lilly paying $6.3 billion for an orexin drug that has not yet entered Phase 3 trials?

The upfront price of $38 per share represents a 40.5% premium to Centessa’s 30-day volume-weighted average price and a 38% premium to its closing price on March 30, 2026. For that, Lilly is acquiring a pipeline that remains entirely pre-commercial, with cleminorexton still awaiting the start of pivotal Phase 3 trials. The premium reflects two things: competitive urgency and the structural scarcity of high-quality OX2R agonist assets. Orexin receptor biology has attracted intense pharmaceutical interest precisely because it addresses the root cause of disorders such as narcolepsy type 1, where patients have lost the orexin-producing neurons that regulate wakefulness, rather than simply managing symptoms with stimulants. The clinical differentiation story for cleminorexton, which has demonstrated activity across three distinct excessive daytime sleepiness indications compared with Takeda’s narrower focus on narcolepsy type 1, gave Lilly a rationale to pay a premium that a single-indication asset would not have justified.

Beyond the lead asset, the deal includes a second clinical-stage compound, ORX142, which has completed Phase 1 studies in healthy volunteers and is preparing to enter patient trials. Centessa also holds a portfolio of preclinical OX2R agonists with potential applications across neurodegenerative and neuropsychiatric conditions, giving Lilly a broader scientific platform rather than a one-drug bet. The contingent value right structure, which conditions up to $9 per share in additional payments on specific FDA approval milestones for cleminorexton or ORX142 by defined deadlines, signals that Lilly’s board was willing to share downside risk with Centessa shareholders rather than overpay upfront on uncertain regulatory outcomes. A hard cutoff of January 1, 2030, on one of the milestone tranches introduces a concrete timeline that will govern how aggressively Lilly accelerates clinical execution after the deal closes in the third quarter of 2026.

How does cleminorexton compare with Takeda’s oveporexton and other orexin agonists in clinical development?

Takeda Pharmaceutical Company’s oveporexton, formerly TAK-861, remains the most clinically advanced OX2R agonist, having met all primary and secondary endpoints across two large Phase 3 trials, FirstLight and RadiantLight, in narcolepsy type 1 patients in July 2025. Takeda has breakthrough therapy designation from the U.S. Food and Drug Administration for oveporexton, and the company is on track to become the first to seek approval for this class. Industry analysts have estimated oveporexton’s peak annual sales potential at between $2 billion and $3 billion in narcolepsy type 1 alone.

Cleminorexton’s competitive argument rests on breadth rather than speed. Takeda has indicated it does not plan to advance oveporexton in narcolepsy type 2, and the drug’s twice-daily dosing requirement gives competitors with once-daily formulations a potential adherence advantage over time. Centessa has positioned cleminorexton as having demonstrated activity across three indications in Phase 2a, covering narcolepsy type 2 and idiopathic hypersomnia in addition to narcolepsy type 1, a profile that could support a broader commercial label if replicated in Phase 3. Alkermes is developing alixorexton (ALKS 2680), which has also shown Phase 2 data and is advancing toward Phase 3. Jazz Pharmaceuticals, the current market leader in narcolepsy through its oxybate franchise under the Xyrem and Xywav brands, halted its own OX2R agonist program in Phase 1 due to safety concerns, leaving it as an incumbent increasingly exposed to class disruption rather than a credible orexin innovator.

The broader competitive map in narcolepsy is complicated by the fact that OX2R agonists have faced safety signals across multiple programs, including hepatotoxicity in earlier Takeda compounds and visual disturbances reported with other candidates. Cleminorexton has not disclosed comparable signals in its Phase 2a data, but the compound has not yet been exposed to the patient volumes or trial duration of a pivotal study. Lilly will need to establish a clean safety profile at scale as Phase 3 design and execution become its immediate priorities post-acquisition.

What does the Centessa deal reveal about Eli Lilly’s neuroscience strategy beyond obesity and Alzheimer’s disease?

Eli Lilly enters this deal as one of the most cash-generative pharmaceutical companies in the world, with analysts estimating the company generated over $15 billion in free cash flow in 2025, driven by the exceptional commercial performance of Mounjaro and Zepbound in cardiometabolic health. That cash generation capacity has funded a prolific deal pace. In 2025, Lilly completed acquisitions including Scorpion Therapeutics for oncology, Verve Therapeutics for cardiovascular gene editing, Ventyx Biosciences for immunology, and Orna Therapeutics for cell therapy, among roughly 40 business development transactions across therapeutic areas. The Centessa acquisition, which multiple reports confirm is Lilly’s fourth acquisition in the past year alone in neuroscience-adjacent space, is by far the largest of that recent run.

Lilly’s neuroscience portfolio prior to this deal was anchored by Kisunla, its approved amyloid-clearing antibody for Alzheimer’s disease, and brenipatide, a Phase 3 candidate for alcohol use disorder and major depressive disorder. What it lacked, according to RBC Capital Markets analyst Brian Abrahams, was a position in sleep disorders, which he described as a nearly commercial, multibillion-dollar market where Lilly had been conspicuously absent despite growing exposure across depression, pain, and neurodegeneration. The Centessa acquisition directly closes that gap, and the appointment of Carole Ho as executive vice president and president of Lilly Neuroscience in late 2025 suggested the strategic intent predated the deal announcement.

The deal also carries a logic that extends well beyond narcolepsy. Orexin biology is being investigated for its potential role in neurodegenerative conditions including Alzheimer’s disease, where disrupted sleep-wake cycles are both a symptom and potentially a contributing mechanism. Centessa’s preclinical pipeline specifically references utility in neurodegenerative and neuropsychiatric disorders, creating optionality that could allow Lilly to connect its orexin assets to its Kisunla franchise in future combination or sequencing strategies. Whether that potential ever converts to a marketed therapy is speculative, but it reframes the acquisition as a platform investment rather than a simple narcolepsy play.

What are the execution and regulatory risks Lilly faces in integrating Centessa’s orexin pipeline after closing?

The primary execution challenge is clinical acceleration under a structurally demanding timeline. Cleminorexton has not yet entered Phase 3, and the milestone payment tied to a first U.S. FDA approval prior to January 1, 2030, means Lilly has approximately three and a half years from the expected Q3 2026 closing to design, enroll, complete, and file at least one pivotal study. Narcolepsy trials have historically required large, multicenter enrollment and extended observation periods to capture the full symptom profile of the disorder. The pace at which Lilly can stand up Phase 3 infrastructure using its global regulatory and clinical operations capabilities will be the most consequential variable in determining whether the CVR payments ever trigger.

Regulatory complexity is layered on top of that timeline pressure. Narcolepsy type 2 and idiopathic hypersomnia have less mature regulatory precedent than narcolepsy type 1, and idiopathic hypersomnia in particular involves evolving diagnostic criteria and limited approved treatments that could complicate endpoint design and FDA interaction. The milestone structure, which assigns separate payment tranches to narcolepsy type 2 approval and idiopathic hypersomnia approval in addition to a first approval in any indication, signals that Lilly’s counterparties at Centessa understood those risks and priced them into a contingent rather than upfront structure.

Integration risk is a secondary but material concern. Centessa was structured as a focused clinical-stage organization, and its scientific identity as a pioneer in orexin biology is central to the cultural and intellectual capital that Lilly is paying to acquire. Large pharmaceutical integrations historically struggle to preserve the speed and scientific agility of acquired biotechs, and Lilly’s leadership has publicly acknowledged that post-acquisition execution speed matters. The transaction is being conducted as a scheme of arrangement under English and Welsh law, which requires sanction by the High Court of Justice in addition to Centessa shareholder approval and customary regulatory clearances, adding procedural steps that are standard for UK-domiciled targets but extend the timeline to close.

How are markets responding to the Lilly-Centessa deal and what does analyst sentiment indicate about strategic value?

Eli Lilly shares closed at $919.77 on March 31, 2026, the day the acquisition was announced, and surged approximately 5.46% on April 1, driven in part by a separate and significant catalyst: the FDA approved Foundayo (orforglipron), Lilly’s oral weight-loss drug, on April 1, its second approved obesity treatment. The convergence of two major positive developments in 48 hours makes it difficult to isolate the market’s precise verdict on the Centessa transaction alone, but the absence of any negative reaction to a $6.3 billion outlay for a pre-Phase 3 pipeline is itself instructive. Investors have consistently demonstrated a willingness to reward Lilly’s dealmaking as long as acquisitions extend rather than dilute the scientific platform that has driven its extraordinary valuation recovery from a 52-week low of $623.78 in August 2025.

Analyst sentiment has been broadly supportive. RBC Capital Markets described the acquisition as filling a material gap in Lilly’s neuroscience coverage, while Barclays characterized it as complementary to the existing neuroscience division. The consensus 12-month price target for Lilly shares stands at approximately $1,209, implying meaningful upside from current levels, and 24 of 25 analysts tracked by Investing.com maintained buy-equivalent ratings as of early April 2026. The size of the deal relative to Lilly’s free cash flow generation capacity means it does not materially alter the company’s balance sheet flexibility or its ability to pursue additional transactions, preserving optionality for further pipeline augmentation.

Centessa shares responded as expected, trading to approximately the $38 offer price following the announcement. Entities affiliated with Medicxi Ventures, Index Ventures, and General Atlantic have signed voting support agreements covering approximately 24.1% of Centessa’s outstanding ordinary shares, providing a floor of committed support that reduces completion risk from the shareholder vote perspective. The deal remains subject to court sanction and regulatory approval, with a Q3 2026 close targeted.

What does Lilly’s entry into orexin agonists mean for Jazz Pharmaceuticals and the narcolepsy treatment market?

Jazz Pharmaceuticals currently dominates the narcolepsy treatment market through its sodium oxybate products, Xyrem and Xywav, which address excessive daytime sleepiness and cataplexy through a mechanism that has little in common with orexin biology. The emergence of OX2R agonists represents the most credible structural threat Jazz has faced, as orexin agonists offer a mechanistically distinct approach that may be preferred by patients and prescribers who seek treatments that engage the underlying biology of wakefulness rather than relying on scheduled controlled substances. Takeda’s oveporexton, which is closest to market, is the near-term pressure point for Jazz. Lilly’s entry, operating on a longer timeline via cleminorexton, adds a second major commercial competitor to the horizon.

For Harmony Biosciences, whose pitolisant franchise competes in narcolepsy through a different wakefulness-promoting mechanism, the orexin wave presents a similar challenge. Harmony has its own preclinical OX2R agonist program in BP1.15205, with a first-in-human study planned for the second half of 2025 and topline data expected in 2026, but it is many years behind both Takeda and Centessa in clinical maturity. The net effect of Lilly’s acquisition is to raise the capital intensity and scientific credibility of OX2R competition, potentially accelerating consolidation among smaller orexin programs that cannot match the development firepower that Lilly brings. The narcolepsy market, historically a niche area dominated by a handful of specialty products, is rapidly becoming one of the more contested battlegrounds in neuroscience.

Key takeaways: What the Eli Lilly acquisition of Centessa Pharmaceuticals means for investors, competitors, and the sleep medicine market

• Eli Lilly is paying $6.3 billion upfront and up to $7.8 billion in total for an entirely pre-Phase 3 pipeline, reflecting competitive urgency and the scarcity of broad-spectrum OX2R agonist assets at clinical scale.
• Cleminorexton’s Phase 2a data across three indications, narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia, gives it a potentially wider commercial label than Takeda’s oveporexton, which is focused on narcolepsy type 1.
• The contingent value right structure, with a hard January 1, 2030, deadline on one tranche, is a de facto timeline commitment that will govern clinical execution priorities for Lilly’s neuroscience leadership.
• Lilly’s fourth neuroscience-area acquisition in the past year confirms a deliberate strategy to build a comprehensive brain-health portfolio alongside its cardiometabolic dominance, with Kisunla in Alzheimer’s disease and brenipatide in psychiatry flanking the new sleep medicine vertical.
• Jazz Pharmaceuticals faces a second major commercial orexin agonist threat on the horizon, compounding the pressure from Takeda’s oveporexton, and has no comparable program in late-stage development.
• Alkermes remains the only other well-capitalized independent player with Phase 2 OX2R agonist data, and its position is likely to attract renewed strategic attention from acquirers now that Lilly has set a valuation benchmark.
• The deal structure, executed as a scheme of arrangement under English and Welsh law, requires High Court sanction in addition to shareholder and regulatory approvals, extending the procedural timeline relative to a standard U.S. merger agreement.
• Lilly’s cash generation from its GLP-1 franchise funds the acquisition without material balance sheet strain, preserving deal capacity for additional transactions across its pipeline priorities.
• Orexin biology’s potential relevance to neurodegenerative conditions, including sleep disruption in Alzheimer’s disease, creates platform optionality that extends the investment thesis beyond narcolepsy alone.
• Centessa’s founding investor coalition, including Medicxi Ventures, Index Ventures, and General Atlantic, has committed to voting in favor, covering approximately 24.1% of outstanding shares and reducing completion risk materially.